Cardiovascular Diseases Clinical Trial
Official title:
Effect of n-3 Fatty Acid Supplementation in Hyperlipidemic Patients Taking Statins, on Lipid Profile, Including Small Dense LDL: A Randomized, Placebo-controlled, Double-blind Trial.
Epidemiological and clinical evidence suggests that high-dose intake of long-chain n-3 fatty
acids have a favorable role in altering blood TG and non-HDL cholesterol when combined with
statins in hyperlipidemic patients. Their efficacy in altering low density lipoprotein
cholesterol particle size and concentration is yet to be confirmed.
This study evaluates the effects of adding 4/day eicosapentaenoic acid (EPA) +
docosahexaenoic acid (DHA) to stable statin therapy on blood TG, non-HDL, LDL-C as well as
small dense (sdLDL) particle concentration in a group of hyperlipidemic patients.
In this randomized, placebo-controlled, double-blind parallel group study, 44 subjects who
were already on statin therapy for > 8 weeks and had non-HDL-C levels above the National
Lipid Association Recommendations were randomized into two groups. For 8 weeks, together with
their prescribed atorvastatin, the intervention group received 4g/day EPA+DHA (in ethyl ester
form) while the control group received 4g/day olive oil (placebo). Baseline measurements of
non-HDL-C, TG, TC, HDL-C, LDL-C, VLDL-C and sdLDL were repeated at week 8. Differences in
dietary intake were assessed with a weighed 3-day food diary at week 4. Primary outcome
measures are the percent change in non-HDL-C and sdLDL particle concentration from baseline
to the end.
This study is a parallel randomised, double-blind placebo - controlled trial which was
conducted in Istanbul, Turkey.
BACKGROUND
Cardiovascular disease (CVD) has been, and still is the number 1 cause of deaths all over the
world. According to the World Health Organisation (WHO), 1 of every 3 death was caused by CVD
in 2012. Heart disease and stroke were the No. 1 and No. 2 killers worldwide, according to
American Heart Association. In Turkey, it is even worse, 40% of all deaths were caused by
CVD. Such high prevalence naturally brings a huge disease burden and in many countries there
are ongoing research to mitigate CVD risk.
It is essential to highlight that CVD is not a single disease, it is actually a family of
diseases that mostly cause by a common pathology named "atherosclerosis". Atherosclerosis is
plaque formation in artery walls which leads a reduced lumen diameter, causing organ damage
or clinical events like myocardial infarction (MI), angina or stroke. One of the two reasons
of atherosclerosis is hyperlipidemia, which is the theme of this study. Atherosclerosis and
lipids are evident to be related; the elevations in circulating LDL cholesterol level plays a
central role in atherogenesis, given the fact that they cause the formation of fatty plaque.
Therefore, in all clinical guidelines, LDL level is the primary target to prevent
atherosclerosis.However, more recent studies have revealed that LDL is structurally
heterogeneous based on its size and density. There are large, buoyant LDL particles and
small, dense LDL particles, which are believed to be more atherogenic. Individuals that have
a large amount of small and dense LDL particles are at an increased risk of CV events,
regardless of their total LDL level. In studies, small and dense LDL profile was associated
with a three-fold to seven-fold increase in risk of CVD as they:1- Have the increased ability
to penetrate arterial wall. 2- Are readily oxidized.
The main therapeutic approach to treat small&dense LDL is using drugs that lower serum
triglyceride (TG) levels, as they also cause a change in the LDL size profile to larger, less
dense and, therefore, less atherogenic species. Most commonly used such drugs are statins.
Apart from statins, there is strong evidence that omega-3 fatty acids also have a beneficial
effect in lowering TGs. However, their effect on small, dense LDL has not been studied enough
yet. If omega-3 fatty acids have a beneficial effect in changing LDL profile to less dense
and larger particles, omega-3 supplementation will be quite effective for patients with
hyperlipidemia. Given the fact that statin use is the gold standard in all clinical
guidelines, this study will not compare statins with omega-3 fatty acids and instead, compare
statin monotherapy to the combined use of statin and omega-3 supplements to investigate
whether omega-3 fatty acids have a supportive role to statin.
RECRUITMENT AND SAMPLING:
Eligible participants were men or women from Istanbul, Turkey, aged between 50 and 79 years
who had been receiving a stable dose of atorvastatin for the control of LDL-C levels at least
for 8 weeks before initial screening.
One hundred patients were selected for initial screening and 44 matched the
inclusion/exclusion criteria and were randomized to the intervention using
www.randomization.com.
Participants were informed informally via telephone first, and then invited to the Clinic by
a Patient Invitation Letter. A structured one-to-one information session was carried out with
each participant at the Clinic, during which they were given a Participant Information Sheet.
Participants provided written informed consent by signing the a Participant Consent Form.
SAMPLE-SIZE
Total sample size was 44, consisting of two 22-subject groups (control and intervention
group).
A targeted sample size of 36 subjects (18 per arm) was expected to provide at least 80% power
to detect a difference of 5% or above in primary outcome non-HDL-C and LDL-C III particle
concentration when compared with placebo (α=0.05) . Sample size was assigned as 44 to allow
for subject attrition and other potential causes of study withdrawal up to 20%.
The power calculation was based on the mean changes in non-HDL-C measurement of the previous
COMBOS trial which is a largest randomized placebo controlled trial that has the same design
with this study. Data from COMBOS trial is summarized as follows:
Intervention Group:
baseline non-HDL mean + standard deviation (SD): 135.8 mg/dL + 24.5 mg/dL final non-HDL mean
+ SD: 124.1 mg/dL + 24.7 mg/dL Percent change: -7.9%
Placebo Group:
baseline non-HDL mean +SD: 141.3 mg/dL + 29.3 mg/dL final non-HDL mean + SD: 138.8 mg/dL +
32.0 mg/dL Percent change: -1.5%
METHODS
A randomized, double-blind, placebo controlled, parallel groups study was carried out. Before
entry into the intervention phase of the study, 8-weeks of dietary lead-in was carried out.
Study participants received dietary counselling for the 8 weeks before the intervention,
based on the heart-healthy diet structured in the United Kingdom (UK) National Institute of
Health Care Excellence (NICE) guidelines (2014) and were instructed to maintain this diet
throughout the study. Adherence to dietary advice was also measured by a 3-day weighed intake
food diary at Week 4. Household measures were used to assess the food intake. Nutrient
content of the diet was estimated using Nutritics software (Nutritics Ltd, Ireland) using UK:
Scientific Advisory Committee on Nutrition (SACN) 2015 food composition tables.
After the dietary lead-in, baseline measurements of fasting blood Triglycerides (TG), Total
Cholesterol (TC), High-density Lipoprotein cholesterol (HDL-C), Low-density Lipoprotein
cholesterol (LDL-C), and LDL-C sub groups (LDL-C I, LDL-C II, LDL-C III, LDL-C IV, LDL-C V)
were carried out for all subjects at 2 clinics separated by 1 week, and the means were used
as baseline values. Non-High-density Lipoprotein cholesterol (non-HDL-C) was calculated by
subtracting HDL-C from TC.
After baseline measurements, all participants were randomized in equal numbers to receive
either 4g/day EPA (75%) & DHA (25%) ethyl esters or 4g/day olive oil (placebo) for 8 weeks in
combination with the same dose of atorvastatin they had been prescribed. For all subjects,
atorvastatin dosage was kept constant throughout the trial.
Both groups consumed four 1000mg capsules orally 4 times daily and compliance was measured by
the number of capsules consumed relative to the number estimated to be consumed.
Baseline measurements were repeated at the end of week 8. Study participants and
investigators remained blinded to all laboratory results until completion of analysis.
BIOCHEMICAL MEASUREMENTS
Laboratory analyses were performed by e-Lab Laboratories (Istanbul, Turkey) on the serum or
plasma of 12 hours fasting blood samples. LDL-C, VLDL-C and HDL-C was measured with
homogeneous enzymatic colorimetric assay of Roche Diagnostics (USA). TG and TC was measured
with enzymatic colorimetric assay of Roche Diagnostics (USA). LDL-C subgroups were analyzed
with electrophoresis by Lipoprint (Quantimetrix, USA).
STATISTICAL ANALYSIS
Statistical analyses was be performed with Statistical Package for the Social Sciences (SPSS)
version 24 (IBM, USA).
Demographic and baseline analysis was performed for all study participants, while efficacy
analysis was performed only on subjects that successfully completed the 8-week study
protocol. The primary efficacy end points are non-HDL and LDL-C III particle concentration
percentage change from baseline; secondary efficacy end points are changes in TG, TC, LDL-C,
VLDL-C and HDL-C.
Normal distribution of the sample was checked with Shapiro-Wilk's test. Mixed model ANOVA
test was carried out to compare changes in outcome parameters from baseline to
end-of-treatment between the intervention and control groups.
Paired t-tests were performed to analyze the changes from baseline to Week 8 for each outcome
parameter, and multiple Independent t-tests were performed to analyze significant differences
between groups across time points. A P-value < 0.05 determined statistical significance.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Recruiting |
NCT04515303 -
Digital Intervention Participation in DASH
|
||
Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
Recruiting |
NCT04417387 -
The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
|
||
Not yet recruiting |
NCT06211361 -
Cardiac Rehabilitation Program in Patients With Cardiovascular Disease
|
N/A | |
Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
Recruiting |
NCT04514445 -
The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
|
||
Enrolling by invitation |
NCT04253054 -
Chinese Multi-provincial Cohort Study-Beijing Project
|
||
Completed |
NCT03273972 -
INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers
|
N/A | |
Completed |
NCT03680638 -
The Effect of Antioxidants on Skin Blood Flow During Local Heating
|
Phase 1 | |
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Completed |
NCT04083872 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting)
|
Phase 1 | |
Completed |
NCT04083846 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed)
|
Phase 1 | |
Completed |
NCT03619148 -
The Incidence of Respiratory Symptoms Associated With the Use of HFNO
|
N/A | |
Completed |
NCT03693365 -
Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
|
||
Completed |
NCT03466333 -
Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia
|
Phase 2 | |
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Completed |
NCT05132998 -
Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors
|
N/A | |
Completed |
NCT05067114 -
Solutions for Atrial Fibrillation Edvocacy (SAFE)
|